Hansoh Pharmaceutical Group, a Chinese drugmaker partnered with Roche, exceeded profit expectations for 2025 with a 27% increase in annual earnings. The company's success was driven by innovative medicine sales and lucrative licensing agreements with international pharmaceutical companies.
SHANGHAI – Chinese pharmaceutical company Hansoh Pharmaceutical Group announced impressive financial results on Sunday, surpassing analyst predictions with a 27% boost in yearly profits driven by innovative drug sales and strategic business partnerships.
The drugmaker, which maintains a partnership with global pharmaceutical giant Roche, specializes in treatments for cancer, infections, neurological disorders, metabolic conditions, and autoimmune diseases. The company has successfully navigated China’s government-led bulk purchasing programs that have pressured generic drug profits by focusing on licensing deals and developing cutting-edge medications.
Annual net earnings for the fiscal year ending December 31, 2025, reached 5.56 billion yuan (equivalent to $804.44 million), significantly exceeding the analyst consensus estimate of 4.97 billion yuan compiled by LSEG.
The pharmaceutical company also reported strong revenue growth, with yearly sales climbing 22.6% to reach 15.03 billion yuan.
A major contributor to Hansoh’s success was a licensing agreement signed with Roche in October, valued at up to $1.45 billion for an experimental cancer treatment targeting colorectal cancer and other solid tumor types.
This Roche partnership was among several international licensing deals completed last year, including agreements with Glenmark Pharmaceuticals’ Swiss division and Regeneron Pharmaceuticals, demonstrating the company’s expanding global reach.
Life Continues Near Iraq-Iran Border Despite Ongoing Conflict
Afghanistan Hit by Deadly Weather: 17 Killed in Floods and Landslides
Derby Car Attack Leaves 7 Injured, Driver Arrested for Attempted Murder
Catholic Cardinal Barred from Holy Sepulchre Church During Palm Sunday Service